Nephrology Forum
Kidney International (2004) 65, 341–355; doi:10.1111/j.1523-1755.2004.00437.x
Treatment of primary IgA nephropathy
The Nephrology Forum is funded in part by grants from Amgen, Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorporated; and Bristol-Myers Squibb Company.
EFSTATHIOS ALEXOPOULOS Principal discussant:
Hippokration General Hospital, Thessaloniki, Greece
Correspondence: Dr Efstathios Alexopoulos, Department of Nephrology, Hippokration General Hospital, Thessaloniki, Greece. E-mail:nephrol@med.auth.gr
Keywords:
glomerulonephritis, end-stage renal disease, renal transplantation, ACE inhibitors, angiotensin II-receptor blockers, immunosuppressive therapy, fish oil therapy
